Thank you to our speakers, sponsors, and delegates who joined us at the 12th Alzheimer’s & Parkinson’s Drug Development Summit! If you are interested in the 2025 event, please get in touch at info@hansonwade.com
After a 17-year hiatus in drug approvals for neurodegeneration, disease-modifying drugs for AD have finally broken the ice. With Lecanemab’s clinically proven 30% reduction in cognitive decline receiving the green light from the FDA & PMDA and Eli Lilly’s Donanemab hot on their heels for approval, 58 new trials entering the pipeline this year, and the alpha-synuclein self-seeding assay changing the game for PD drug development.
The 12th Alzheimer’s & Parkinson’s Drug Development Summit is indisputably the ultimate industry-focused meeting dedicated to sharing the hottest unpublished AD & PD research from senior biopharma KOLs you won’t hear anywhere else, with deep-dive content all the way from early discovery through to late phase trials and approvals.
This April, join 150+ senior industry leaders across discovery, preclinical, biomarker, translational, clinical, and commercial this year from Eli Lilly, Biogen, Eisai, Abbvie, Merck, Michael J. Fox Foundation, Acumen, Vigil Neuroscience, and many more….
2024 Expert Speakers Included:
Pallavi Sachdev
Executive Director Translational Science, Clinical Evidence Generation, Deep Human Biology (CEG DHBL)
Eisai
Samantha Hutten
Director, Discovery & Translational Research
The Michael J. Fox Foundation for Parkinson's Research
Attending Companies Included:
What Have Your Peers Said?
"Alzheimer’s & Parkinson’s Drug Development Summit is a great venue to develop meaningful collaborations in a pre-competitive environment to narrow the unmet gap and truly address patient needs." - Executive Director, Eisai
"This meeting has a range of presenters throughout various industry organizations. Topics cover a wide breadth of information on critical topics from the bench to the clinic for Alzheimer’s and Parkinson’s diseases, including recent advances in the field as well as areas that require further
advancement." - Associate Scientific Director, Biogen
"Access to the most up-to-date progress in an exciting and fast-paced field." - Chief Executive Officer, Aprinoia
"This event features an intimate setting which gives you the opportunity to talk to your peers and delve into the details in depth to make it a very productive, concentrated, and focused program that makes it very attractive venue for learning the cutting edge of the field and casual interactions with great speakers and leaders in the arena." - VP & Head of Non-Clinical & Translational Research, Seelos Therapeutics
Our 2024 Partners:
Our 2024 Media Partners:
Other Events in the World CNS Series
